Market Cap
$14.5M
PASG
Passage BIO, Inc.
$4.11 ▼ -2.17%
Prev close $4.20Market cap$14.5M
12-mo target$15.50 (+277.1%)
High Impact Filing (8/10)3 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on PASG right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
17 funds
Inst. Value
$6.3M
Inst. Activity
0 buys / 3 sells
Insider Activity
$206.1K buy / $0.00 sell
Insider Net $
$206.1K
SEC Reports
8
Press Releases
2
Price chart 30d -10.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 3, 2026 SEC Sep 3, 2026 SEC
Passage Bio filed an amended S-4 (S-4/A) detailing its proposed reverse merger with Remix Therapeutics, where Remix will
S-4/A, 425 — Impact 8/10
Passage Bio (PASG) is acquiring Remix Therapeutics in a reverse-merger transaction valued at $226M for Remix's equity, w
8-K — Impact 8/10
Aug 10, 2026 earnings_calendar
PASG Q2 2026 Earnings Scheduled — 2026-08-10
Jun 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
47,892 shares ($233.7K)
Jun 30, 2026 Inst.
Jun 25, 2026 SEC Erste Asset Management GmbH — TRIM
40,665 shares ($197.2K)
Passage Bio entered into a definitive all-stock merger agreement with Remix Therapeutics, where pre-merger Passage share
8-K — Impact 7/10
Jun 25, 2026 Insider
Lynx1 Capital Management LP bought 50,055 shares
10%+ Owner @ $4.12 ($206.1K)
May 19, 2026 Insider
Countouriotis Athena was granted 10,539 shares
Director
Analyst ratings buy % -27.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Apr 21, 2026 | TD Cowen | DOWNGRADE | Hold | 56% |
| Apr 21, 2026 | Chardan Capital | DOWNGRADE | Neutral | 49% |
| Apr 21, 2026 | Oppenheimer | MAINTAIN | Outperform | 52% |
| Apr 21, 2026 | Wedbush | DOWNGRADE | Neutral | 57% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Aug 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Jul 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Jun 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% | |
| May 1, 2026 | 3 | 4 | 5 | 0 | 0 | 58% | |
| Apr 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% |
Price targets
Where 2 covering analysts think PASG trades over the next 12 months.
$15.50 +277.1% upside Strong Buy
Current$4.11 Low$8.00 Median$15.50 High$23.00 2 analysts
$8.00$23.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 1 bullish, 5 bearish, 1 mixed, 1 neutral · avg impact 6.4/10.Plus 2 press releases.
BEARISHS-4/A, 4258/10
Passage Bio filed an amended S-4 (S-4/A) detailing its proposed reverse merger with Remix Therapeuti
Sep 3, 2026
BULLISH8-K8/10
Passage Bio (PASG) is acquiring Remix Therapeutics in a reverse-merger transaction valued at $226M f
Sep 3, 2026
BEARISH8-K7/10
Passage Bio entered into a definitive all-stock merger agreement with Remix Therapeutics, where pre-
Jun 25, 2026
BEARISH4257/10
Passage Bio filed a definitive all-stock merger agreement to acquire Remix Therapeutics, where pre-m
Jun 25, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 10, 2026
earnings_calendar
PASG Q2 2026 Earnings Scheduled — 2026-08-10
Jun 24, 2026
m_and_a
Passage Bio and Remix Therapeutics Announce Merger Agreement
Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing
May 11, 2026
earnings_calendar
PASG Q1 2026 Earnings Scheduled — 2026-05-11
Apr 20, 2026
fda
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing b
Mar 3, 2026
earnings
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-2.82 | $-3.75–$-1.89 | -15.6% | +0.0% | — | $0.0B | 2 |
| Next Q | $-2.83 | $-4.06–$-1.61 | 30.7% | +0.0% | — | $0.0B | 2 |
| Current FY | $-11.34 | $-14.08–$-8.60 | 21.0% | +0.0% | — | $0.0B | 2 |
| Next FY | $-10.39 | $-11.55–$-9.23 | 8.4% | +0.0% | — | $0.0B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-2.820 | — |
| 7d ago | $-2.820 | — |
| 30d ago | $-2.820 | — |
| 60d ago | $-3.013 | +0.193 |
| 90d ago | $-2.527 | -0.292 |
Institutional ownership
Which big funds own PASG (from quarterly 13F filings) and who is adding or trimming.
17 institutional holders with $6.3M total value (3,307,329 shares) as of 2026-Q2. Top holders: CITADEL, VANGUARD, BALYASNY. Net selling activity: 3 institutions trimmed/exited vs 0 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | 2,886,125 | $4.3M | 68.4% | DOUBLED +154.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 113,964 | $556.1K | 8.8% | — |
| BALYASNY ASSET MANAGEMENT L.P. | 107,025 | $522.3K | 8.3% | — |
| RENAISSANCE TECHNOLOGIES LLC | 47,892 | $233.7K | 3.7% | TRIM -64.2% |
| Erste Asset Management GmbH | 40,665 | $197.2K | 3.1% | TRIM -52.3% |
| GEODE CAPITAL MANAGEMENT, LLC | 37,026 | $180.7K | 2.9% | ADD +31.8% |
| BlackRock, Inc. | 27,910 | $136.2K | 2.2% | — |
| VANGUARD FIDUCIARY TRUST CO | 17,049 | $83.2K | 1.3% | — |
| UBS Group AG | 13,565 | $66.2K | 1.1% | TRIM -50.7% |
| MORGAN STANLEY | 2,389 | $11.7K | 0.2% | TRIM -38.0% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 133,612 | 47,892 | -64.2% | $233.7K |
| Erste Asset Management GmbH | TRIM | 85,262 | 40,665 | -52.3% | $197.2K |
| UBS Group AG | TRIM | 27,501 | 13,565 | -50.7% | $66.2K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 31,397 | 41,380 | +31.8% | $324.9K |
| UBS Group AG | DOUBLED | 1,442 | 27,501 | +1807.1% | $215.9K |
| MORGAN STANLEY | TRIM | 4,275 | 2,650 | -38.0% | $20.8K |
| Rockefeller Capital Management L.P. | ADD | 500 | 800 | +60.0% | $6.3K |
| OSAIC HOLDINGS, INC. | TRIM | 20 | 15 | -25.0% | $117.00 |
| Erste Asset Management GmbH | TRIM | 122,790 | 85,262 | -30.6% | $1.0M |
| Squarepoint Ops LLC | TRIM | 23,500 | 10,799 | -54.0% | $127.4K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 9 transactions. Net $206.1K — $206.1K bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 25, 2026 | Lynx1 Capital Management LP | 10%+ Owner | BUY | 50,055 | $4.12 | $206.1K |
| May 19, 2026 | Countouriotis Athena | Director | AWARD | 10,539 | — | — |
| May 19, 2026 | GOWEN MAXINE | Director | AWARD | 10,539 | — | — |
| May 19, 2026 | Kapadia Sandip | Director | AWARD | 10,539 | — | — |
| May 19, 2026 | Porter Derrell | Director | AWARD | 10,539 | — | — |
| May 19, 2026 | Kassberg Thomas Richard | Director | AWARD | 10,539 | — | — |
| May 19, 2026 | Sondhi Dolan | Director | AWARD | 10,539 | — | — |
| Mar 16, 2026 | Chou William | PRESIDENT AND CEO | AWARD | 58,000 | — | — |
| Mar 16, 2026 | Borthwick Kathleen | CFO | AWARD | 15,610 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PASG.
Shares short
97,008
Settlement Sep 15, 2026
Change vs prior
-4.6%
Semi-monthly cycle
Days to cover
3.2
At avg daily volume
Of shares outstanding
≈3.0%
Estimate — not % of float
All PASG filing & press-release reports (10)
- S-4/A, 425 reportSep 3, 2026
- 8-K reportSep 3, 2026
- 8-K reportJun 25, 2026
- 425 reportJun 25, 2026
- 425 reportJun 25, 2026
- 8-K reportJun 5, 2026
- 8-K reportApr 20, 2026
- PRESS-RELEASE reportApr 20, 2026
- DEFA14A reportApr 7, 2026
- PRESS-RELEASE reportMar 3, 2026